Media Updates

PARIS, FRANCE 30 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today a new global collaboration and option agreement with Origami Therapeutics for a research stage protein degrader program targeting genetic neurodegenerative diseases. Following a successful drug candidate nomination,…

PARIS, FRANCE, 9 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) is aware of recent updates on the potential challenges with regards to the manufacturing and availability of generic lanreotide in several markets.  Ipsen stands ready to supply Somatuline (60mg, 90mg, 120mg) at…

PARIS, FRANCE AND MONTREAL, CANADA 22 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR, of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal, announced today a new research collaboration…

PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen’s Board Member and a representative…

PARIS, FRANCE, 14 OCTOBER 2025 – Ipsen (Euronext: IPN: ADR: IPSEY) announced today that its Board of Directors has been informed of the conclusion of a new agreement1 between Highrock (controlled by Anne Beaufour), Beech Tree (controlled by Henri Beaufour)…